• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

    10/24/24 4:05:00 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INSM alert in real time by email

    —Insmed Leads Science Top Employers List for Fourth Year in a Row—

    BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics.

    "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year," said Will Lewis, Chair and Chief Executive Officer of Insmed. "This past year has been transformational for our company, as we've demonstrated the strength of our commercial and pipeline programs, continued to fuel the innovation engine behind our early-stage research, and enhanced our culture while growing to more than 1,200 employees around the world. Looking to the future, I am filled with pride and excitement as I think about the talent, dedication, and potential of our team as we strive to make a real difference in the lives of patients with serious diseases."

    The 2024 survey results were based on nearly 6,500 responses from individuals located primarily across North America (65%), Europe (19%), and Asia/Pacific Rim (11%). This year's highest-ranking companies stood out in the areas of innovative leadership, respect for employees, social responsibility, employee loyalty, and personal and professional value alignment.

    "The culture we've built at Insmed is unlike any other I've experienced, and I am proud to see it continue to grow and strengthen as we expand our global team," said Nicole Schaeffer, Chief People Strategy Officer of Insmed. "Thank you to our colleagues around the world who show up every day with a desire to help patients, enrich our communities, and support one another. It is because of you that we have once again been recognized by Science as the top employer in the biopharma industry."

    The complete feature and company rankings can be accessed here. To learn more about Insmed's culture and explore opportunities to join our team, please visit https://insmed.com/culture/careers/.

    About Insmed

    Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed's most advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company's early-stage research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue.

    Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Insmed is proud to be recognized as one of the best employers in the biopharmaceutical industry, including spending four consecutive years as the No. 1 Science Top Employer. Visit www.insmed.com to learn more.

    Contact:

    Investors:

    Bryan Dunn

    Executive Director, Investor Relations

    Insmed

    (646) 812-4030

    [email protected]  

    Media:

    Mandy Fahey

    Vice President, Corporate Communications

    Insmed

    (732) 718-3621

    [email protected] 

    (PRNewsfoto/Insmed Incorporated)

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-ranks-no-1-on-sciences-2024-top-biopharma-employers-list-302286466.html

    SOURCE Insmed Incorporated

    Get the next $INSM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Q&A

    New
    • What ranking did Insmed achieve in Science's 2024 Top Employers Survey?

      Insmed Incorporated was ranked No. 1 in Science's 2024 Top Employers Survey for the fourth consecutive year.

    • How many responses were collected for the 2024 Top Employers Survey?

      The survey was based on nearly 6,500 responses from employees primarily in North America, Europe, and the Asia/Pacific Rim.

    • What characteristics did the highest-ranking companies exhibit in the survey?

      The survey highlighted qualities such as innovative leadership, respect for employees, social responsibility, employee loyalty, and personal and professional value alignment as key factors for the top ranking.

    • What is the size of Insmed's workforce and what areas do they focus on?

      Insmed has grown to more than 1,200 employees globally and has advanced several programs in pulmonary and inflammatory conditions.

    • What type of products and research does Insmed focus on?

      Insmed is advancing a diverse portfolio that includes approved and investigational medicines, with a significant focus on therapies for chronic and debilitating lung diseases.

    Recent Analyst Ratings for
    $INSM

    DatePrice TargetRatingAnalyst
    8/13/2025$126.00Overweight → Equal-Weight
    Morgan Stanley
    5/13/2025$105.00Buy
    Jefferies
    2/25/2025$100.00Outperform
    RBC Capital Mkts
    4/23/2024$48.00Buy
    Truist
    2/15/2024$42.00Outperform
    Wolfe Research
    12/8/2023$55.00Overweight
    Wells Fargo
    11/20/2023$36.00Overweight
    JP Morgan
    7/26/2023$50.00Buy
    Guggenheim
    More analyst ratings

    $INSM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Insmed Incorporated

    SCHEDULE 13G/A - INSMED Inc (0001104506) (Subject)

    8/14/25 1:07:20 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    8/12/25 4:37:13 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - INSMED Inc (0001104506) (Filer)

    8/12/25 11:55:42 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Desjardins Clarissa bought $201,694 worth of shares (3,025 units at $66.68) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    5/22/25 5:20:35 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief People Strategy Officer Schaeffer Orlov S Nicole sold $1,273,363 worth of shares (10,000 units at $127.34), decreasing direct ownership by 11% to 79,764 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    8/18/25 4:19:48 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md sold $1,215,800 worth of shares (10,000 units at $121.58), gifted 21,100 shares and received a gift of 5,000 shares, decreasing direct ownership by 5% to 284,516 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    8/14/25 4:21:46 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chair and CEO Lewis William exercised 6,830 shares at a strike of $10.85 and sold $750,008 worth of shares (6,830 units at $109.81) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    8/6/25 4:21:35 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

    — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed to Host Investor Conference Call Today at 12:00 PM ET  — BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious

    8/12/25 11:34:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports Second-Quarter 2025 Financial Results and Provides Business Update

    —ARIKAYCE® (amikacin liposome inhalation suspension) Total Revenue of $107.4 Million for the Second Quarter of 2025, Reflecting 19% Growth Over the Second Quarter of 2024— —NDA for Brensocatib in Patients with Bronchiectasis Remains on Track, with a PDUFA Target Action Date of August 12, 2025— —TPIP Program Advancing with Phase 3 Studies Planned to Begin for PH-ILD in the Second Half of 2025 and for PAH in Early 2026— —Topline Data Anticipated for Phase 2b BiRCh Study of Brensocatib in Patients with CRSsNP by the End of 2025— —Company Reiterates 2025 Global ARIKAYCE Revenue Guidance Range of $405 Million to $425 Million, Reflecting Double-Digit Growth Compared to 2024— BRIDGEWATER, N.J., Aug

    8/7/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Insmed downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Insmed from Overweight to Equal-Weight and set a new price target of $126.00

    8/13/25 8:02:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Insmed with a new price target

    Jefferies initiated coverage of Insmed with a rating of Buy and set a new price target of $105.00

    5/13/25 9:43:52 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RBC Capital Mkts initiated coverage on Insmed with a new price target

    RBC Capital Mkts initiated coverage of Insmed with a rating of Outperform and set a new price target of $100.00

    2/25/25 7:09:15 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Leadership Updates

    Live Leadership Updates

    View All

    OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee

    PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass' or ‘the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of experience in investment banking, equity capital markets, corporate finance and business development in the healthcare sector. She currently serves on the Board of Directors for Insmed Incorporated (NAS

    8/6/25 7:00:00 AM ET
    $IMNM
    $INSM
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Ranks No. 1 on Science's 2024 Top Biopharma Employers List

    —Insmed Leads Science Top Employers List for Fourth Year in a Row— BRIDGEWATER, N.J., Oct. 24, 2024 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it has earned the highest ranking in Science's 2024 Top Employers Survey. The annual survey polls employees in biotechnology, pharmaceutical, and related industries to determine the 20 best employers, as well as their driving characteristics. "It is a tremendous honor to have been named the No. 1 employer in Science's annual survey for the fourth consecutive year

    10/24/24 4:05:00 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Names Drayton Wise Chief Commercial Officer

    BRIDGEWATER, N.J., May 23, 2022 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced the appointment of Drayton Wise as Chief Commercial Officer, effective May 23, 2022. In addition to his current responsibilities leading the global ARIKAYCE® (amikacin liposome inhalation suspension) franchise and U.S. commercial activities, Mr. Wise will assume responsibility for all of Insmed's global commercial functions. Mr. Wise will also serve as a member of Insmed's Executive Committee. "We are thrilled to promote Drayton to Chief Commercial Officer at this critical inflecti

    5/23/22 8:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Insmed Incorporated

    SC 13G - INSMED Inc (0001104506) (Subject)

    9/3/24 5:22:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Insmed Incorporated (Amendment)

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    2/16/24 5:43:57 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $INSM
    Financials

    Live finance-specific insights

    View All

    FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

    — Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB — — BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting Neutrophilic Inflammation, Is Available by Prescription Through a Comprehensive Specialty Pharmacy Network — — Insmed to Host Investor Conference Call Today at 12:00 PM ET  — BRIDGEWATER, N.J., Aug. 12, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious

    8/12/25 11:34:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025

    BRIDGEWATER, N.J., July 24, 2025 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that it will release its second-quarter 2025 financial results on Thursday, August 7, 2025. Insmed management will host a conference call for investors beginning at 8:00 a.m. ET on Thursday, August 7, 2025, to discuss financial results and provide a business update. Shareholders and other interested parties may participate in the conference call by dialing (888) 210-2654 (U.S.) and (646) 960-0278 (international) and referencing acces

    7/24/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Announces Positive Topline Results from Phase 2b Study of Treprostinil Palmitil Inhalation Powder (TPIP) as Once-Daily Therapy in Patients with Pulmonary Arterial Hypertension

    –The Study Met Primary and All Secondary Efficacy Endpoints– Statistically Significant 35% Placebo-Adjusted Reduction from Baseline in Pulmonary Vascular Resistance for the Primary Endpoint (p<0.001) 35.5 Meter Placebo-Adjusted Improvement in Six-Minute Walk Distance for the Secondary Efficacy Endpoint (p=0.003) 60% Placebo-Adjusted Reduction from Baseline in NT-proBNP Concentrations for the Secondary Efficacy Endpoint (p<0.001) Results Were Assessed Approximately 24 Hours After Administration, Demonstrating Sustained Benefit Throughout the 24-Hour Dosing Period–TPIP Was Well Tolerated in the Study, with 75% of Patients Titrating to the Highest Dose– –Insmed to Immediately Engage with FDA t

    6/10/25 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care